AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 7 - (NewsRx Network) -- A study published in the May 2001 issue of the Journal of Lower Genital Tract Disease reports that prototypes of a non-invasive cervical cancer detection device being jointly developed by Welch Allyn, Inc., and SpectRx, Inc. (SPRX), detected 25% more disease than Pap smears.
The study of 111 women conducted at two U.S. sites also showed that the performance of the prototypes was not affected by age, history of childbirth, or previous cervical surgical history and generated results across an age range of 18 to 73 years old.
The prototype devices, developed by SpectRx and Welch Allyn, use proprietary biophotonic technology to locate cancers and precancers painlessly and non-invasively by analyzing light reflected from the cervix. The reflected light creates an image of the cervix indicating the location and severity of disease. The technology distinguishes between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level.
Unlike Pap smears or human papillomavirus tests, the SpectRx/Welch Allyn approach does not require a tissue sample or laboratory analysis ...
Source: HighBeam Research, New Test Detects 25% More Disease Than Pap Smears.(SpectRx/Welch...